Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeLatest newsTwo scientists win the 2019 Dr. Paul Janssen Award for biomedical research
      2019 Dr. Paul Janssen Award winners Arthur Horwich, M.D., (left) and Franz-Ulrich Hartl, M.D.

      Two scientists win the 2019 Dr. Paul Janssen Award for biomedical research

      Learn about the revolutionary work they’re both doing in the field of neurodegenerative disease that could prove important in fighting often-fatal conditions.

      Share Article
      share to

      Parkinson’s disease. Huntington’s disease. Lou Gehrig’s disease.

      It’s neurodegenerative illnesses like these that this year’s winners of the Dr. Paul Janssen Award for Biomedical Research are focusing their extraordinary talents on decoding.

      Franz-Ulrich Hartl, M.D., of the Max Planck Institute of Biochemistry in Germany, and Arthur Horwich, M.D., of the Yale School of Medicine and Howard Hughes Medical Institute in the U.S., were chosen for the award based on their groundbreaking insights into a process called chaperone-mediated protein folding and its importance in cellular health—particularly in preventing proteins from aggregating in a way that could potentially lead to the fatal symptoms neurodegenerative diseases can cause.

      Dr. Hartl and Dr. Horwich join 16 scientists who’ve received the award to date, including three who ultimately went on to win the Nobel Prize.

      Honoring scientific pioneers like Dr. Paul Janssen

      Johnson & Johnson created the award in 2004 to honor Paul Janssen, Ph.D., the innovative founder of what is now called the Janssen Pharmaceutical Companies of Johnson & Johnson.

      Each year, the award is given to the most passionate and creative scientist or scientists in basic or clinical research whose achievements have made, or have strong potential to make, a measurable impact on human health through the diagnosis, treatment or prevention of disease.

      Dr. Hartl and Dr. Horwich, who were selected by an independent committee of world-renowned researchers, join 16 scientists who’ve received the award to date, including three who ultimately went on to win the Nobel Prize.

      They’ll share a $200,000 cash prize to further their work and each receive a sculpture with an inspirational inscription of “What’s New?” It’s a nod to the question Dr. Paul, as he was affectionately known, asked daily in his lab to encourage his colleagues to seek new ways to help patients—and inspire the next big health breakthroughs.

      Along with David Julius, Ph.D., who won the Dr. Paul Janssen Award in 2013, Drs. Hartl and Horwich were also just honored with the 2020 Breakthrough Prize in Life Science for the transformative advances they’ve made toward understanding living systems and extending human life.

      More from Johnson & Johnson

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

      What is a gene mutation?

      Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. For DNA Day learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.